Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Epithelial-mesenchymal transition in human prostate cancer demonstrates enhanced immune evasion marked by IDO1 expression.

Kolijn K, Verhoef EI, Smid M, Böttcher R, Jenster GW, Debets R, van Leenders GJ.

Cancer Res. 2018 Jun 19. pii: canres.3752.2017. doi: 10.1158/0008-5472.CAN-17-3752. [Epub ahead of print]

PMID:
29921693
2.

Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3 + 4 = 7 and highest Gleason score 3 + 4 = 7 or > 3 + 4 = 7.

Verhoef EI, Kweldam CF, Kümmerlin IP, Nieboer D, Bangma CH, Incrocci L, van der Kwast TH, Roobol MJ, van Leenders GJ.

Histopathology. 2018 Apr;72(5):760-765. doi: 10.1111/his.13427. Epub 2018 Jan 14.

PMID:
29094386
3.

A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.

Chua MLK, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V, Mahamud O, Gopalan A, Kweldam CF, van Leenders GJLH, Verhoef EI, Hoogland AM, Livingstone J, Berlin A, Dal Pra A, Meng A, Zhang J, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Fradet Y, Têtu B, Reuter VE, Fleshner N, Fraser M, Boutros PC, van der Kwast TH, Bristow RG.

Eur Urol. 2017 Nov;72(5):665-674. doi: 10.1016/j.eururo.2017.04.034. Epub 2017 May 13.

PMID:
28511883
4.

CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.

Zoni E, Chen L, Karkampouna S, Granchi Z, Verhoef EI, La Manna F, Kelber J, Pelger RCM, Henry MD, Snaar-Jagalska E, van Leenders GJLH, Beimers L, Kloen P, Gray PC, van der Pluijm G, Kruithof-de Julio M.

Oncogene. 2017 Aug 17;36(33):4739-4749. doi: 10.1038/onc.2017.87. Epub 2017 Apr 10.

5.

Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.

Böttcher R, Dulla K, van Strijp D, Dits N, Verhoef EI, Baillie GS, van Leenders GJ, Houslay MD, Jenster G, Hoffmann R.

Oncotarget. 2016 Oct 25;7(43):70669-70684. doi: 10.18632/oncotarget.12204.

6.

Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma.

Kweldam CF, Kümmerlin IP, Nieboer D, Verhoef EI, Steyerberg EW, Incrocci L, Bangma CH, van der Kwast TH, Roobol MJ, van Leenders GJ.

Eur J Cancer. 2016 Oct;66:26-33. doi: 10.1016/j.ejca.2016.07.012. Epub 2016 Aug 11.

PMID:
27522247
7.

Three-dimensional microscopic analysis of clinical prostate specimens.

van Royen ME, Verhoef EI, Kweldam CF, van Cappellen WA, Kremers GJ, Houtsmuller AB, van Leenders GJ.

Histopathology. 2016 Dec;69(6):985-992. doi: 10.1111/his.13022. Epub 2016 Sep 21.

PMID:
27353346
8.

MET expression during prostate cancer progression.

Verhoef EI, Kolijn K, De Herdt MJ, van der Steen B, Hoogland AM, Sleddens HF, Looijenga LH, van Leenders GJ.

Oncotarget. 2016 May 24;7(21):31029-36. doi: 10.18632/oncotarget.8829.

9.

Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.

Kweldam CF, Kümmerlin IP, Nieboer D, Verhoef EI, Steyerberg EW, van der Kwast TH, Roobol MJ, van Leenders GJ.

Mod Pathol. 2016 Jun;29(6):630-6. doi: 10.1038/modpathol.2016.49. Epub 2016 Mar 4.

10.

Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma.

De Herdt MJ, Willems SM, van der Steen B, Noorlag R, Verhoef EI, van Leenders GJ, van Es RJ, KoljenoviÄ S, Baatenburg de Jong RJ, Looijenga LH.

Oncotarget. 2016 Mar 15;7(11):13167-81. doi: 10.18632/oncotarget.7534.

11.
12.

Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer.

Böttcher R, Hoogland AM, Dits N, Verhoef EI, Kweldam C, Waranecki P, Bangma CH, van Leenders GJ, Jenster G.

Oncotarget. 2015 Feb 28;6(6):4036-50.

13.

SYK is a candidate kinase target for the treatment of advanced prostate cancer.

Ghotra VP, He S, van der Horst G, Nijhoff S, de Bont H, Lekkerkerker A, Janssen R, Jenster G, van Leenders GJ, Hoogland AM, Verhoef EI, Baranski Z, Xiong J, van de Water B, van der Pluijm G, Snaar-Jagalska BE, Danen EH.

Cancer Res. 2015 Jan 1;75(1):230-40. doi: 10.1158/0008-5472.CAN-14-0629. Epub 2014 Nov 11.

14.

Validation of stem cell markers in clinical prostate cancer: α6-integrin is predictive for non-aggressive disease.

Hoogland AM, Verhoef EI, Roobol MJ, Schröder FH, Wildhagen MF, van der Kwast TH, Jenster G, van Leenders GJ.

Prostate. 2014 May;74(5):488-96. doi: 10.1002/pros.22768. Epub 2013 Dec 27.

PMID:
24375374

Supplemental Content

Loading ...
Support Center